TGTX Stock - TG Therapeutics, Inc.
Unlock GoAI Insights for TGTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $329.00M | $233.66M | $2.79M | $6.69M | $152,000 |
| Gross Profit | $290.52M | $219.53M | $2.52M | $5.90M | $152,000 |
| Gross Margin | 88.3% | 94.0% | 90.5% | 88.2% | 100.0% |
| Operating Income | $41.93M | $20.63M | $-218,316,000 | $-344,770,000 | $-273,594,000 |
| Net Income | $23.38M | $12.67M | $-223,812,000 | $-348,101,000 | $-279,381,000 |
| Net Margin | 7.1% | 5.4% | -8036.3% | -5204.1% | -183803.3% |
| EPS | $0.16 | $0.09 | $-1.46 | $-2.63 | $-2.42 |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 6th 2025 | H.C. Wainwright | Resumed | Buy | $60 |
| July 10th 2025 | Goldman | Resumed | Neutral | $37 |
| October 29th 2024 | TD Cowen | Initiation | Buy | $50 |
| August 2nd 2023 | Goldman | Upgrade | Neutral | $12← $16 |
| June 26th 2023 | Jefferies | Resumed | Buy | $40← $55 |
| May 20th 2022 | BofA Securities | Initiation | Underperform | $5 |
Earnings History & Surprises
TGTXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 2, 2026 | $0.25 | — | — | — |
Q4 2025 | Nov 3, 2025 | $0.24 | $2.43 | +912.5% | ✓ BEAT |
Q3 2025 | Aug 4, 2025 | $0.32 | $0.17 | -46.9% | ✗ MISS |
Q2 2025 | May 5, 2025 | $0.18 | $0.03 | -83.3% | ✗ MISS |
Q1 2025 | Mar 3, 2025 | $0.08 | $0.15 | +87.5% | ✓ BEAT |
Q4 2024 | Nov 4, 2024 | $0.03 | $0.02 | -33.3% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-0.05 | $0.04 | +180.0% | ✓ BEAT |
Q2 2024 | May 1, 2024 | $-0.04 | $-0.07 | -96.0% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $-0.12 | $-0.09 | +25.0% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $0.12 | $0.73 | +508.3% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $-0.26 | $-0.34 | -30.8% | ✗ MISS |
Q2 2023 | May 1, 2023 | $-0.36 | $-0.28 | +22.2% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.26 | $-0.39 | -50.0% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.33 | $-0.26 | +21.2% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.49 | $-0.30 | +38.8% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.55 | $-0.51 | +7.3% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-0.62 | $-0.70 | -12.9% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.56 | $-0.65 | -16.1% | ✗ MISS |
Q3 2021 | Aug 2, 2021 | $-0.48 | $-0.59 | -22.9% | ✗ MISS |
Q2 2021 | May 10, 2021 | $-0.52 | $-0.69 | -32.7% | ✗ MISS |
Latest News
JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $49
📈 PositiveTG Therapeutics EPS of $2.43, revenue of $161.71M beats by $9.54M
📈 PositiveTG Therapeutics Raises FY2025 Sales Guidance from $585.000M to $600.000M vs $588.045M Est
📈 PositiveTG Therapeutics Q3 EPS $2.43 Beats $0.22 Estimate, Sales $161.709M Beat $152.169M Estimate
📈 PositiveTG Therapeutics Completes Enrollment In Phase 3 ENHANCE Trial Evaluating Simplified Dosing Schedule For BRIUMVI
📈 PositiveIHC Wainwright & Co. Assumes TG Therapeutics at Buy, Announces Price Target of $60
📈 PositiveTG Therapeutics Reports Near-Zero Relapse Rate After 6 Years Of BRIUMVI Treatment In Multiple Sclerosis, With No New Safety Signals
📈 PositiveB. Riley Securities Maintains Buy on TG Therapeutics, Raises Price Target to $55
📈 PositiveTG Therapeutics To Present Long-Term BRIUMVI® Data In Relapsing MS At ECTRIMS 2025, Including Six-Year ULTIMATE I & II Results And Real-World ENABLE Study Updates
📈 PositiveTG Therapeutics To Present Long-Term BRIUMVI Data In Relapsing MS At ECTRIMS 2025, Including Six-Year ULTIMATE I & II Results And Real-World ENABLE Study Updates
📈 PositiveTG Commenced Enrollment Phase 3 Trial For Subcutaneous BRIUMVI
📈 PositiveTG Therapeutic shares are trading higher after the company announced a $100 million repurchase program.
📈 PositiveTG Therapeutics Authorizes New $100M Repurchase Program
📈 PositiveTG Therapeutics falls after Q2 miss despite guidance raise
📉 NegativeTG Therapeutics stock sinks on profit miss
📉 NegativeFrequently Asked Questions about TGTX
What is TGTX's current stock price?
What is the analyst price target for TGTX?
What sector is TG Therapeutics, Inc. in?
What is TGTX's market cap?
Does TGTX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TGTX for comparison